Trial
NCT02505087
Pharmacological Treatment of a Rare Genetic Disease: N-acetylcysteine in Myopathy Associated Selenoprotein N-related Myopathy (SEPN1-RM)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
—
Condition
Selenoprotein N-related Myopathy
Intervention
N-Acetylcysteine followed by Placebo
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-09-29